Stock Update (NYSE:MRK): AiCuris and Merck Announce Publication in New England Journal of Medicine of Phase 2 Clinical Trial Results of Investigational Antiviral Agent Letermovir in Bone Marrow Transplant Patients

[Business Wire] – AiCuris and Merck , known as MSD outside the United States and Canada, today announced the publication of results from a Phase 2 clinical trial evaluating the safety and efficacy . . . → Read More: Stock Update (NYSE:MRK): AiCuris and Merck Announce Publication in New England Journal of Medicine of Phase 2 Clinical Trial Results of Investigational Antiviral Agent Letermovir in Bone Marrow Transplant Patients Similar Articles: Market Update: Merck & Co Inc (NYSE:MRK) – Merck to Hold Investor Briefing at Boston Research Facility Company Update (NYSE:MRK): Merck to Hold First-Quarter 2014 Sales and Earnings Conference Call on April 29 Merck & Co. Inc. (NYSE:MRK) – 8:31 am Merck initiates rolling submission of U.S. Biologics License Application for MK-3475, an investigational Anti-PD-1 Immunotherapy, in patients with advanced melanoma; expects to complete application in 1H14